Indication
Fetal and Neonatal Alloimmune Thrombocytopenia
2 clinical trials
2 products
Clinical trial
An Exploratory Clinical Study of the Safety and Efficacy of CD19 Chimeric Antigen Receptor NK Cell Injections for the Treatment of Refractory Primary Immune ThrombocytopeniaStatus: Not yet recruiting, Estimated PCD: 2025-03-30
Product
anti-CD19 CAR NK cellsClinical trial
A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a AlloimmunizationStatus: Not yet recruiting, Estimated PCD: 2027-05-01